Product
iC9/CAR.19/IL15-Transduced CB-NK Cells
1 clinical trial
4 indications
Indication
B-Lymphoid MalignanciesIndication
Acute Lymphocytic LeukemiaIndication
Chronic Lymphocytic LeukemiaIndication
Non-Hodgkin LymphomaClinical trial
Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid MalignanciesStatus: Completed, Estimated PCD: 2023-03-06